Please login to the form below

Not currently logged in
Email:
Password:

Lu AE58054

This page shows the latest Lu AE58054 news and features for those working in and with pharma, biotech and healthcare.

Lundbeck trial failure dashes hopes in Alzheimer's once again

Lundbeck trial failure dashes hopes in Alzheimer's once again

Idalopirdine (Lu AE58054) appeared to be safe and showed evidence of "weak efficacy" in the phase III STARSHINE study, which enrolled patients with mild to moderate Alzheimer's.

Latest news

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Pharma deals during March 2013 Pharma deals during March 2013

    Otsuka will also share development expenses as Lu AE58054 progresses later this year into its pivotal clinical programme comprising several studies and over 2, 500 patients. ... The first phase III study in patients with mild-to-moderate Alzheimer's

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics